鱼油是从富含脂肪的鱼类中提取的一种油脂。它富含二十碳五烯酸 (EPA) 、二十二碳六烯酸 (DHA) 和多种 N-3 多不饱和脂肪酸 (N-3PUFA) ，这些都是人体必需的不饱和脂肪酸。 EPA 可以清理血管垃圾，软化血管，提高免疫力，被称为"血管清道夫"； DHA 常用于孕妇和婴幼儿。服用 DHA 可以促进大脑的正常生长发育，从而起到所谓的健脑益智作用，俗称"脑黄金"。 据 QYResearch 调研团队最新报告"全球鱼油 EPA 和 DHA 市场报告 2025-2031 "显示，预计 2031 年全球鱼油 EPA 和 DHA 市场规 模将达到 20.2 亿美元，未来几年年复合增长率 CAGR 为 3.4% 。 鱼油 EPA 和 DHA ，全球市场总体规模 全球 鱼油 EPA 和 DHA 市场前 20 强生产商排名及市场占有率（基于 2 02 4 年调研数据；目前最新数据以本公司最新调研数据为 准） 根据 QYResearch 头部企业研究中心调研，全球范围内鱼油 EPA 和 DHA 生产商主要包括 KD Pharma 、 Croda 、 BASF 、禹王制 药、 GC Rieber VivoMega 、 ...

According to the judges, the winning factors placing ProGo® well ahead of the competition are its unique ability to activate GLP-1 and GIP receptors, coupled with its unrivalled sustainability credentials including Upcycled Certified by WFCF (Where Food Comes From). Most significantly, these benefits are supported and evidenced through two clinical studies demonstrating weight loss with ProGo®. ProGo® Bioactive Peptides optimize the metabolism of glucose and fat to improve energy levels and weight profile. ...

棕榈油酸是一种天然存在的单不饱和脂肪酸。它广泛存在于动植物脂肪中，尤其常见于海洋鱼油、乳制品和某些植物油中。棕榈油酸可在人 体内通过棕榈酸脱氢生成。它具有抗炎、促进新陈代谢和促进皮肤健康等生物学功能，常用于食品、化妆品和保健品行业。棕榈油酸，也称 为棕榈油酸酯或 (9Z)- 十六碳烯酸酯，属于长链脂肪酸有机化合物。长链脂肪酸是指带有 13 至 21 个碳原子的脂肪族链段的脂肪酸。棕榈油 酸是一种疏水性极强的分子，几乎不溶于水，且呈中性。 棕榈油酸， C16 ： 1 酸，俗称 Omega-7 脂肪酸，科学界对其对许多重要健康应用的潜在益处进行了研究，包括心脏健康、抗炎、胰岛素敏 感性、补充粘膜水分以及对皮肤、头发和指甲的抗衰老功效。 据 QYResearch 调研团队最新报告"全球棕榈油酸市场报告 2025-2031 "显示，预计 2031 年全球棕榈油酸市场规模将达到 0.9 亿美元，未来几 年年复合增长率 CAGR 为 7.8% 。 棕榈油酸 ，全球市场总体规模 全球 棕榈油酸 市场前 8 强生产商排名及市场占有率（基于 2 02 5 年调研数据；目前最新数据以本公司最新调研数据为准） 根据 QYResea ...

Investor Presentation February 2024 We offer people around the world a better path to wellness and a healthy, vibrant life. Forward Looking Statements SAFE HARBOR ST ATEMENT This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "hopes," "intends," "estimates," "expects," "proj ...

Investor Presentation Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Nasdaq: CDXC | March 2024 Safe Harbor statement This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Stat ...

Core Insights - Cosmos Health Inc. has announced its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC [1][2] - The production will take place in GMP-certified facilities, enhancing operational control and reducing tariff exposure [2][4] - This partnership aims to strengthen Cosmos Health's position in the premium nutraceuticals market and expand its portfolio with scientifically backed ingredients [3][4] Company Overview - Cosmos Health Inc. is a diversified, vertically integrated global healthcare group, owning proprietary pharmaceutical and nutraceutical brands and operating a telehealth platform [6] - The company has established R&D partnerships targeting major health disorders and focuses on innovative product development [6] - Cosmos Health has a global distribution platform and is expanding throughout Europe, Asia, and North America [6] Partnership Details - The agreement with DolCas Biotech is expected to leverage DolCas's expertise in clinically validated formulations and vertically integrated manufacturing [3][4] - DolCas Biotech is recognized for its commitment to quality and innovation, with a portfolio that includes clinically supported nutraceutical products [5] - The partnership is seen as a strategic move to support Cosmos Health's growth in the U.S. and globally [4]

Revolutionary Canine Supplement Promotes Regenerative Healing Through Stem Cell ActivationLAS VEGAS , June 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC Pink: BDPT), an innovator in nutraceutical and wellness science, today announces the upcoming national release of Pawpa™ Regen, a proprietary canine supplement that supports natural stem cell activation and regenerative healing in aging dogs. After a successful limited market release earlier this year, Pawpa™ Regen officially launches nati ...

Core Viewpoint - The global market for plant-based soft capsules for supplements is projected to reach USD 575.39 million by 2031, with a compound annual growth rate (CAGR) of 5.4% from 2025 to 2031 [2]. Market Overview - The global market for plant-based soft capsules is expected to grow significantly, with the top ten manufacturers holding approximately 84.0% of the market share by 2024 [7]. - The main product type currently dominating the market is carrageenan, which accounts for about 89.3% of the market share [9]. - In terms of application, vitamin and mineral supplements represent the largest demand source, holding approximately 35.5% of the market share [12]. Industry Trends - The trend of vegetarian soft capsules replacing gelatin soft capsules is expected to continue, driven by the advantages of vegetarian options, such as being non-animal sourced and suitable for a wider audience [13]. - The popularity of gellan gum products is increasing, as gellan gum is a non-toxic, odorless, and tasteless ingredient that enhances the stability and bioavailability of active ingredients in soft capsules [13][14]. Challenges - High price levels due to significant R&D investments and high raw material costs are a challenge for manufacturers [15]. - Continuous R&D investment is necessary to meet market demands, as the nutritional health food industry experiences rapid product updates and requires substantial funding and technical expertise [15]. Growth Drivers - Vegetarian soft capsules are more popular in developed countries, with significant market shares in the U.S., Europe, and Japan [16]. - There is a growing demand for vegetarian products in Middle Eastern and African countries, particularly in Islamic regions [17].

Core Insights - Glow Lifetech Corp. has achieved significant market momentum in Ontario, expanding its retail distribution to over 1,000 licensed stores, marking a 45% increase year-to-date and establishing itself as the 2 ranked oil brand with its MOD™ line [2][3][4] Group 1: Retail Expansion - The company has expanded its retail footprint to over 1,000 stores in Ontario, reflecting strong demand for its differentiated product portfolio [2][3] - This expansion is expected to continue, further solidifying Glow's position as a category leader in the province [2][3] Group 2: Brand Performance - Glow's flagship MOD™ brand has advanced to become the 2 ranked oil brand in Ontario, indicating a growing base of loyal consumers and successful product launches [3][4] - The sustained growth trajectory of both MOD™ and .decimal™ brands is supported by strong commercial traction and record demand [3][4] Group 3: Product Innovation - Glow launched MOD™ CBN:THC Drops in May 2025 and secured a new listing for MOD™ CBN:CBD Drops in early June, both of which have seen strong customer demand [5] - These new products tap into the rising demand for CBN-based formulations, reinforcing Glow's commitment to developing innovative cannabis products [5]

Major commercial expansion of its U.S. strategy through logistics and distribution agreementNEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports and other products, today announced a major expansion of its U.S. commercial strategy through an exclusive logistics and distribution agreem ...